Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Research output: Contribution to journal › Journal article › Research › peer-review
Natalizumab, a highly specific a4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.
Original language | English |
---|---|
Journal | Lancet Neurology |
Volume | 10 |
Issue number | 8 |
Pages (from-to) | 745-58 |
Number of pages | 14 |
ISSN | 1474-4422 |
DOIs | |
Publication status | Published - 2011 |
ID: 40198112